Medicines such as Ozempic, Wegovy and other GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. They can help control blood sugar, reduce appetite and support substantial weight loss.
A large study examining the wider effects of these medications found that GLP-1 drugs were associated with numerous potential health benefits. However, the researchers also identified several possible risks, including a higher rate of arthritic disorders.
The finding does not prove that Ozempic directly causes arthritis. It should instead be understood as a potential safety signal that requires further investigation.
What the Large Study Examined
The research was published in Nature Medicine in January 2025. Researchers analyzed medical information from the US Department of Veterans Affairs to map the possible benefits and risks associated with GLP-1 receptor agonists.
The study included more than 215,000 people with diabetes who started a GLP-1 medication. Their health outcomes were compared with those of patients using other common diabetes treatments, as well as a usual-care group.
Researchers examined 175 different health outcomes affecting the cardiovascular, digestive, neurological, kidney, respiratory and musculoskeletal systems. The large dataset allowed them to develop a broad picture of how GLP-1 medicines may affect different parts of the body.
What the Study Found About Arthritis
People using GLP-1 receptor agonists showed an increased risk of what the researchers described as arthritic disorders when compared with some of the other diabetes-treatment groups.
This category can include conditions associated with joint inflammation, stiffness, swelling and pain. However, the study was designed to detect broad associations across many medical conditions. It was not specifically created to determine whether semaglutide causes a particular type of arthritis.
The researchers therefore could not confirm exactly why the association appeared. It may reflect a direct medication effect, differences between the patient groups or other health and lifestyle factors that were not fully captured in the medical records.
The authors classified arthritic disorders among several outcomes that appeared more frequently in GLP-1 users. Other increased risks included digestive problems, low blood pressure, fainting, kidney stones, interstitial nephritis and medication-related pancreatitis.
The Drugs Were Also Associated With Important Benefits
The study did not conclude that GLP-1 medicines were broadly harmful. In fact, the researchers observed possible benefits across several major areas of health.
GLP-1 use was associated with lower risks of certain cardiovascular conditions, blood-clotting disorders, respiratory illnesses, infections, substance-use disorders and some neurological conditions. The findings also suggested lower risks of dementia and Alzheimer’s disease, although these possible benefits require additional clinical research.
These results show why the overall health profile of GLP-1 medicines is complicated. One medication can provide significant benefits while still creating risks for certain patients or organ systems.
Why the Arthritis Finding Is Complicated
Other research has produced findings that appear to point in the opposite direction.
A randomized clinical trial involving people with obesity and knee osteoarthritis found that once-weekly semaglutide produced greater weight loss and a larger reduction in knee pain than a placebo. The results were published in the New England Journal of Medicine.
Weight loss can reduce mechanical pressure on weight-bearing joints, especially the knees and hips. GLP-1 medications may also have anti-inflammatory effects that could potentially benefit some people with arthritis.
More recent observational research has suggested that sustained GLP-1 use may be associated with a lower long-term risk of knee-replacement surgery among people with osteoarthritis and metabolic conditions. However, researchers and arthritis specialists have stressed that these medications are not currently approved as treatments for osteoarthritis.
The apparently conflicting results may reflect differences in the arthritis conditions studied, the patients included, the comparison groups, medication duration and the outcomes researchers measured.
A drug could potentially reduce knee pain related to obesity while still being associated with a higher rate of another category of joint or inflammatory disorder. More targeted studies are needed before firm conclusions can be drawn.
Why the Study Cannot Prove Ozempic Causes Arthritis
The Nature Medicine research was observational rather than a randomized clinical trial. Researchers examined existing medical records instead of randomly assigning patients to take GLP-1 drugs or another treatment.
This type of study can identify patterns, but it cannot establish cause and effect with certainty.
Patients receiving GLP-1 drugs may differ from other patients in their weight, diabetes severity, previous treatments, physical activity, access to healthcare and underlying medical conditions. Researchers can adjust for many of these factors, but some differences may remain.
The study population was also drawn mainly from the US veteran healthcare system. Most participants were older men with diabetes, so the findings may not apply equally to younger people, women or those using GLP-1 medicines only for weight management.
The research evaluated the GLP-1 drug class as a whole. It should not be interpreted as proof that every medication, dose or individual product carries exactly the same level of arthritis risk.
What Ozempic and Wegovy Users Should Do
Patients should not stop taking a prescribed GLP-1 medication solely because of this study. Suddenly discontinuing diabetes or weight-management treatment can affect blood-sugar control, appetite and body weight.
Anyone who develops persistent joint pain, swelling, stiffness, warmth or reduced movement after beginning a new medication should speak with a healthcare professional. A doctor can evaluate whether the symptoms may be connected to arthritis, an injury, another health condition or a medication.
Patients should also tell their prescriber about any previous history of inflammatory arthritis, kidney disease, pancreatitis, severe digestive problems or fainting episodes before starting treatment.
The US Food and Drug Administration provides information about medication safety and adverse-event reporting. Patients in the United States can also report suspected medication reactions through the FDA’s MedWatch system.
What the Research Means
The study provides a broad map of the possible health effects associated with GLP-1 receptor agonists. Its findings support the established view that these medicines can provide important metabolic and cardiovascular benefits while also carrying potential risks.
The arthritis association deserves further research, but it should not be treated as proof that Ozempic or similar medications directly cause joint disease.
Current evidence remains mixed. Some studies suggest a possible increase in broadly defined arthritic disorders, while others indicate that semaglutide-related weight loss may improve pain and mobility in people who already have knee osteoarthritis.
Treatment decisions should therefore be based on a patient’s complete health profile, treatment goals and medical history rather than a single study or headline.
